61903-27-3

Basic information

• Product Name: 1-Phenyl-[1,4]diazepane
• Synonyms: 1-Phenyl-[1,4]diazepane;4-phenylhomopiperazine;1-phenyl-1,4-diazepane(SALTDATA: CH3COOH);1H-1,4-Diazepine, hexahydro-1-phenyl-;1-Phenyl-[1,4]diazepane hydrochloride
• CAS NO: 61903-27-3
• Molecular Formula: C₁₁H₁₆N₂
• Molecular Weight: 176.26
• Product Categories: pharmacetical
• Mol File: 61903-27-3.mol

Chemical Properties

• Boiling Point: 300.056 °C at 760 mmHg
• Flash Point: 137.559 °C
• Appearance: /
• Density: 1.004 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.533
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-Phenyl-[1,4]diazepane(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Phenyl-[1,4]diazepane(61903-27-3)
• EPA Substance Registry System: 1-Phenyl-[1,4]diazepane(61903-27-3)

Safety Data

• Hazardous Substances Data: 61903-27-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Phenyl-[1,4]diazepane is used as a psychoactive drug for its sedative, anxiolytic, and muscle relaxant properties. It is utilized in the treatment of anxiety disorders, insomnia, and muscle spasms due to its ability to enhance the effects of GABA at the GABA-A receptor.
Used in Recreational Drug Market:
1-Phenyl-[1,4]diazepane has gained popularity as a recreational drug and a designer drug in recent years. However, its potential for abuse and addiction has led to its classification as a controlled substance in many countries.

InChI:InChI=1/C11H16N2/c1-2-5-11(6-3-1)13-9-4-7-12-8-10-13/h1-3,5-6,12H,4,7-10H2

Upstream product

• 505-66-8 1,4-Diazacycloheptane 
• 591-50-4 iodobenzene 
• 112275-50-0 tert-butyl 1,4-diazepine-1-carboxylate 
• 868063-55-2 4-phenyl-1,4-diazepane-1-carboxylic acid tert-butyl ester 
• 108-86-1 bromobenzene 

Downstream Products

• 868063-56-3 (Z)-2-cyano-3-(4-phenyl-1,4-diazepan-1-yl)but-2-enethioamide 
• 1609534-97-5 1-phenyl-4-acetyl-homopiperazine 
• 1609534-98-6 1-phenyl-4-ethyl-homopiperazine 
• 1609534-92-0 1,1-diethyl-4-phenyl-homopiperazinium besylate 
• 1609534-91-9 1,1-diethyl-4-phenyl-homopiperazinium mesylate 
• 1609534-90-8 1,1-diethyl-4-phenyl-homopiperazinium tosylate 
• 1609534-89-5 1,1-diethyl-4-phenyl-homopiperazinium acetate 
• 1609534-87-3 1,1-diethyl-4-phenyl-homopiperazinium chloride 
• 1609534-86-2 1,1-diethyl-4-phenyl-homopiperazinium bromide 
• 1609534-85-1 1,1-diethyl-4-phenyl-homopiperazinium iodide 
• 868063-54-1 3-amino-4-(4-phenyl-1,4-diazepan-1-yl)thieno[2,3-b]pyridine-2-carboxamide 
• 868063-57-4 4-(4-phenyl-1,4-diazepan-1-yl)-2-thioxo-1,2-dihydropyridine-3-carbonitrile 
• 1422423-98-0 C₂₂H₂₄N₄O₂ 
• 1320288-56-9 N-(1-isopropylpiperidin-4-yl)-6-methoxy-2-(4-phenyl-1,4-diazepan-1-yl)-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine 

Relevant articles and documents

METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER

The present disclosure relates to a method for treating cancer comprising administering to a patient in need thereof an effective amount of a compound having the formula: (Formula (I)) wherein R1, R2, Ya, Xa, and J- are as defined herein.

COMBINATION THERAPY AND METHODS FOR THE TREATMENT OF RESPIRATORY DISEASES

The present disclosure relates to novel combination comprising a homopiperazinium compound having the formula (I): wherein J is a counter ion,; and one or more agents for treating or preventing the pulmonary diseases, for use and method for the treatment or prevention of respiratory diseases. Also provided are novel compounds and intermediates as well as processes for preparing same.

Discovery and structure-activity relationship of thienopyridine derivatives as bone anabolic agents

A cell-based assay was performed for the discovery of novel bone anabolic agents. Alkaline phosphatase (ALPase) activity of ST2 cells was utilized as an indicator of osteoblastic differentiation, and thienopyridine derivative 1 was identified as a hit compound. 3-Aminothieno[2,3-b]pyridine-2-carboxamide was confirmed to be a necessary core structure for the enhancement of ALPase activity, and then optimization of the C4-substituent on the thienopyridine ring was carried out. Introduction of cyclic amino groups to the C4-position of the thienopyridine ring improved the activity. Especially, N-phenyl-homopiperazine derivatives were found to be strong enhancers of ALPase among this new series. Furthermore, 3-amino-4-(4-phenyl-1,4-diazepan-1-yl)thieno[2,3-b]pyridine-2- carboxamide (15k) was orally administered to ovariectomized (OVX) rats over 6 weeks for evaluating the effects on areal bone mineral density (aBMD), and statistically significant improvements in aBMD were observed from the dosage of 10 mg/kg/day.

THIENOPYRIDINE DERIVATIVES

The present invention provides a compound promoting osteogenesis. The present invention provides a compound having the following general formula (I) wherein R 1 is H or alkyl, R 2 is R a S-, R a O-, R a NH-, R a (R b )N- or cyclic amino, and R a and R b are alkyl which may be substituted, cycloalkyl which may be substituted, or the like, or a pharmacologically acceptable salt thereof.

Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use

The subject invention provides compounds having the structure: 1 wherein,R1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra;R2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra, orR1, R2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH2)2OH or —CH2C(═O)OH;R3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C1-C15)alkyl, (C1-C15)alkoxy, or —NRaRb;R4 is hydrogen or substituted or unsubstituted (C1-C15)alkyl;R5 is —(CH2)mOR6, —CHNOR7, —C(═O)NR8R9, —(CH2)mC(═O)OR10, —(CH2)kC(═O)NR11R12;wherein R6 is a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring;R7 is hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl;R8 and R9 are each independently hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl, (C1-C30)alkylamino, (C1-C30)alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, orR8, N, and R9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring;R10 is hydrogen or a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or heterocyclic ring;R11, N and R12 together form a 4-8 membered heterocyclic ring;Ra and Rb are each independently hydrogen or alkyl;m is 0, 1, 2 or 3; andk is 1, 2 or 3,or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.

New μ-opioid receptor agonists with piperazine moiety

New μ-opioid receptor (MOR) agonists containing piperazine and homopiperazine moieties in the structures were synthesized and their affinities to and agonist potencies on MOR were evaluated. Among the synthesized compounds, 4-[4-(2-methoxyphenyl)piperazin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide (20Aa) showed the highest affinity to the human MOR expressed in Chinese hamster ovary (CHO)-K1 cells, and the highest agonist potency on the MOR in isolated guinea-pig ileum preparation.